A61K 9 - Medicinal preparations characterised by special physical form

Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044)
10/2002
10/31/2002	WO2002043750A3 Method for the stabilizing of biomolecules (e.g. insulin) in liquid formulations
10/31/2002	WO2002040045A3 Microspheres of pancreatic enzymes with high stability
10/31/2002	WO2002040029A3 Corticosteroids adducts with natural polysaccharide polymers
10/31/2002	WO2002039977A3 A method for restoring a foot fat-pad
10/31/2002	WO2002026217A3 Composition for the transdermal delivery of fentanyl
10/31/2002	WO2002005800A3 Compositions for sustained release of analgesic agents, and methods of making and using the same
10/31/2002	WO2001067896A3 Method of producing oily suspensions of water-soluble vitamins
10/31/2002	WO2001056563A9 Adamantyl derivatives as anti-cancer agents
10/31/2002	WO2001054663A9 Surfactant free topical compositions and method for rapid preparation thereof
10/31/2002	WO2001052918A9 Fluid delivery device with temperature controlled energy source
10/31/2002	US20020161437 Crystalline polymeric compositions for ophthalmic devices
10/31/2002	US20020161354 Implantable drug delivery pump with desiccant humidity protection
10/31/2002	US20020161352 Vaginal ring preparation and application
10/31/2002	US20020161206 For inhibiting tumor cell growth
10/31/2002	US20020161169 Hydrogel-forming system with hydrophobic and hydrophilic components
10/31/2002	US20020161136 Releasing active materials upon degradation
10/31/2002	US20020161054 And treatment of Chronic Obstructive Pulmonary Disease and allergic rhinitis
10/31/2002	US20020161044 Method for enhanced delivery of oxybutynin and compositions thereof
10/31/2002	US20020161042 Nitric oxide donor composition and method for treatment of anal disorders
10/31/2002	US20020161035 Medicaments for chemotherapeutic treatment of disease
10/31/2002	US20020161032 Dosage form of a statin and microparticles of fenofibrate stabilized by a phospholipid surface active substrance; bioavailability unaffected by food intake
10/31/2002	US20020161024 Administering 2-(piperidin-2,6-dion-3-yl),4-amino-isoindolin-1-one to treat an eye condition
10/31/2002	US20020161020 Stablization of quinapril using magnesium oxide
10/31/2002	US20020161017 For amelioration of erectile dysfunction in a mammal without causing substantial intolerable adverse side effects to mammal
10/31/2002	US20020161016 As-needed administration of tricyclic and other non-SRI antidepressant drugs to treat premature ejaculation
10/31/2002	US20020160995 Suspended in a carrier host agent
10/31/2002	US20020160991 Orally-bioavailable formulations of fentanyl and congeners thereof
10/31/2002	US20020160982 Modafinil compound and cyclodextrin mixtures
10/31/2002	US20020160967 Sesame oil, medium-chain triglycerides, glycol esters or fatty acid esters and a cosolvent selected from polyhydric alcohols, cyclic carbonates, acetates, acetals, ketals, or castor oil
10/31/2002	US20020160933 Methods and compositions for producing a neurosalutary effect in a subject
10/31/2002	US20020160508 Fibrin polymer structure
10/31/2002	US20020160415 Methods, pharmaceutical formulations and kits for identification of subjects at risk for cancer and for the prevention of cancer in at- risk subjects
10/31/2002	US20020160191 Low maturing temperature porcelain compositions useful for the fabrication of dental restorations.
10/31/2002	US20020160190 Nanotechnology for magnetic components
10/31/2002	US20020160109 Microencapsulation of drugs by solvent exchange
10/31/2002	US20020160056 Delivering source of iontophoretically deliverable lithium to patient through skin via dermal patch; treatment of acute mania or bipolar disorder
10/31/2002	US20020160053 Solution for promoting growth of tissue cells at wound sites and production process therefor
10/31/2002	US20020160050 Comprising one or more hydrophilic cellulose ether polymers, a hydrophilic melt binder, and a therapeutically active ingredient
10/31/2002	US20020160049 Emulsions as solid dosage forms for oral administration
10/31/2002	US20020160048 Medical formulation containing a muscarinic agonist
10/31/2002	US20020160047 Use of polyalkylamine polymers in controlled release devices
10/31/2002	US20020160046 Delivery system for omeprazole and its salts
10/31/2002	US20020160045 Therapeutic dosage form for delivering oxybutynin
10/31/2002	US20020160044 Liver selective drug therapy
10/31/2002	US20020160043 Dissolvable drug-containing dosage form for use in transmucosal delivery of drug to patient, comprising binding agent formed into solid matrix dissolvable in mouth, pharmacologically effective dosage of drug, buffer
10/31/2002	US20020160042 Injection molding method for neutral and acidic-group containing (meth)acrylate copolymers
10/31/2002	US20020160041 Controlled release pharmaceutical composition
10/31/2002	US20020160040 Cubic liquid crystalline compositions and methods for their preparation
10/31/2002	US20020160039 Infusing lipid/alcohol solution directly into aqueous polymer solution; resulting liposome which may be incorporated with a pharmaceutical substance consists of multilamellar vesicles of average size of 1-8 microns
10/31/2002	US20020160038 Cationic liposome containing cationic lipid, phosphatidylcholine and cholestrol; carrier for radiosensitizing tumor cells by administration of Human antisense c-raf-1 oligodeoxyribonucleotide
10/31/2002	US20020160035 Devices and methods for the release of volatile substances and applications thereof
10/31/2002	US20020160030 Emulsifier-free finely disperse systems of the oil-in-water and water-in-oil type
10/31/2002	US20020160009 For treatment of disseminated candidiasis due to infection by C. albicans; composition includes phosphomannan of C. albicans
10/31/2002	US20020159988 Lytic enzyme produced by bacteria being infected with a bacteriophage specific for such bacteria, useful for treating eye infection
10/31/2002	US20020159987 Use of phage associated lytic enzymes for treating bacterial infections of the digestive tract
10/31/2002	US20020159956 Providing a chewing gum, includes a gum center and a coating coverings, coating includes a drug designed to be delivered into systemic system of indivisual
10/31/2002	US20020159954 Aerodynamically light poly((p-carboxyphenoxy)-hexane anhydride) particles
10/31/2002	US20020159952 Novel acoustically active drug delivery systems
10/31/2002	US20020159951 Administering to the patient a contrast agent comprising, in an aqueous carrier, targeted vesicles formulated from a lipid or polymer, a prfluorocarbon gas, a targeting ligand, scanning the patient using ultrasound to obtain an image
10/31/2002	US20020158226 Functionalized cubic liquid crystalline phase materials and methods for their preparation and use
10/31/2002	US20020157677 Insulin delivery enhanced by coached breathing
10/31/2002	DE10120627A1 Verwendung von Phyllanthusbestandteilen zur Behandlung oder Prophylaxe von Infekten durch Hepatitis B-Viren Use of Phyllanthus for the treatment or prophylaxis of infections caused by hepatitis B viruses
10/31/2002	DE10120428A1 Orales Mittel für die Human- und Veterinärmedizin Oral agent for human and veterinary medicine
10/31/2002	DE10119718A1 Verfahren zur kontinuierlichen Herstellung inhalierfähiger Arzneistoffe, Vorrichtung zur Durchführung des Verfahrens und nach diesem Verfahren hergestellter Arzneistoff A process for the continuous production of inhalable medicaments, apparatus for performing the method and produced by this process drug
10/31/2002	DE10119292A1 Powder pencil lead or chalk for cosmetic use or pastel drawing, comprises fillers and a copolymer of polyethylene glycol and tetramethoxymethylglycoluril
10/31/2002	DE10118852A1 Solid particles for transporting hydrophobic active agents, e.g. drugs or nucleic acids, obtained from organic solvent solution of active agent and water-insoluble and amphiphilic polymers by ultrasonication and dialysis
10/31/2002	CA2791888A1 Proliposomal drug delivery system
10/31/2002	CA2681952A1 Drug delivery matrices to enhance wound healing
10/31/2002	CA2449415A1 Intraoral delivery of nicotine for smoking cessation
10/31/2002	CA2445740A1 Use of metals to treat inflammatory skin conditions
10/31/2002	CA2445734A1 Medicament containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent and their use to induce apoptosis in cancerous tissue
10/31/2002	CA2445729A1 Use of metals to treat mucosal membranes
10/31/2002	CA2444885A1 Methods and compositions for treating oral and esophageal lesions
10/31/2002	CA2444883A1 Microprojection array having a beneficial agent containing coating
10/31/2002	CA2444709A1 Compositions and methods to control bleeding
10/31/2002	CA2444601A1 A release pharmaceutical construct for gastric retention
10/31/2002	CA2443944A1 Agent for prophylaxis or treatment of inflammatory diseases in mucosa of oral cavity and the like
10/31/2002	CA2443937A1 Prostanoids augment ocular drug penetration
10/31/2002	CA2443587A1 Therapeutic treatments using the direct application of antimicrobial metal compositions
10/31/2002	CA2443518A1 Controlled release particles
10/31/2002	CA2441785A1 Fast disintegrating meloxicam tablet
10/31/2002	CA2436273A1 Method for producing an active ingredient concentrate, and an active ingredient concentrate
10/30/2002	EP1252896A2 Colon-specific drug release system
10/30/2002	EP1252893A1 Medicine containing anemonin as effective component for treating aseptic inflammation
10/30/2002	EP1252887A1 Sustained-release preparation and process for producing the same
10/30/2002	EP1252886A1 Controlled release pharmaceutical pellet compositions
10/30/2002	EP1252885A2 Methods of preparing gas and gaseous precursor-filled microspheres
10/30/2002	EP1252884A2 Oral composition for human or veterinairy medicine
10/30/2002	EP1252883A1 Process for reducing partially or completely the symptoms associated with the histamin release within the human body
10/30/2002	EP1252882A1 Process to increase the threshold tolerance of the sensitive skin
10/30/2002	EP1252210A1 Amphiphilic networks, implantable immunoisolatory devices, and methods of preparation
10/30/2002	EP1252175A1 Antisense modulation of survivin expression
10/30/2002	EP1251877A1 Site specific binding system, nuclear imaging compositions and methods
10/30/2002	EP1251873A1 Antagonist of th-1 immuneresponse inducing cytokine for the treatment of autoimmune diseases
10/30/2002	EP1251867A1 Nasal calcitonin formulations
10/30/2002	EP1251864A1 Pharmaceutical formulation composed of a polymer blend and an active compound for time-controlled release
10/30/2002	EP1251862A1 Ophthalmic compositions for treating ocular hypertension
10/30/2002	EP1251858A2 Podophyllotoxin compositions
10/30/2002	EP1251857A1 Pharmaceutical parenteral composition containing a bisphosphonate
10/30/2002	EP1251853A1 Transdermal therapeutic system for the administration of zaleplon

1 ... 2217 2218 2219 2220 2221 2222 2223 2224 2225 2226 2227 2228 2229 2230 2231 2232 2233 2234 2235 2236 2237 ... 2991